Provocative Prescriptions

A glimpse into the uncomfortable world of impotence drug names.

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


(Update 5/5/98: Last month, we asked readers to suggest names for new impotence drugs. And the winner is: Dan Bloom of Andover, Mass., with his imposing Obeliskon. It’s somewhat subtle, certainly evocative, and most importantly, not crude. Congrats, Dan. Your mug is on the way. Honorable mentions go to the promising Arise and Revive, the unmarketable Phalloflate and Schwing!, and the most-suggested name, unfortunately already in use as the name of an impotence drug manufacturer: Upjohn.)

When Pfizer announced a little over a week ago that they had come up with, and been granted FDA approval for, a new impotence drug which could be taken orally, it was big news. They called it Viagra. What’s behind the name? Some people (like myself) immediately think vitality + gushing. But then, we didn’t name it, the folks at Pfizer did. What were they thinking? The MoJo Wire takes a look at the naming of Viagra and other recent impotence drugs:

 

Viagra

Who makes it: Pfizer. 47,000 employees.

Claim to fame: It’s the first pill for impotence, and it only works when the man is aroused.

How the name came about: Pfizer says they just liked the way it sounded, “positive and short—a name people can remember.” It also works in all the major languages. They did point out, without being asked, “It’s not related to the Niagara Falls.”

Rejected names: Pfizer wouldn’t tell us. They don’t want to give any ideas to their competitors.

Downside: It takes an hour to work, and some men’s vision gets a blue tint.

 

Muse

Who makes it: Vivus. 300 employees.

Claim to fame: A catheter like device, it’s applied into the urethra. Works within 15 minutes.

How the name came about: The decidedly non-projectile sounding name is actually an acronym which stands for Medicated Urethral System for Erection. Even though the acronym stands for the method of delivery and not the the actual drug itself, Vivus liked the name so much they decided to use it anyway.

Rejected names: They decided names like “Erect-Med” and “Erectile” were too graphic. Says Michael Miller, spokesperson for Vivus, “We have a very sensitive subject here. People don’t need to be reminded of it every time they get the drug.”

Downside: See “Claim to fame.” Their promotional literature highlights two possible problems: “pain” and “urethral scraping.”

 

Vasomax

Who makes it: Zonagen Inc. 39 employees.

Claim to fame: It’s a pill, just like Viagra, but it only takes 15-30 minutes to work. (FDA approval pending)

How the name came about: It’s a “vasodilator,” meaning it dilates the blood vessels in the penis, allowing blood to flow in. Says a Zonagen spokesperson, “We didn’t do a great deal of research. Plus nobody else was using it.”

Rejected names: None, it was the first name they came up with.

Downside: It’s not on the market yet. Once it is, it will likely be more expensive than Viagra.

 

Caverject

Who makes it: Pharmacia & Upjohn. 30,000 employees

Claim to fame: The active ingredients were introduced to the public at a urology convention when a doctor decided to give a personal demonstration. On the podium, he dropped his pants and proudly revealed an “impressively erect penis”—results brought on, he pointed out, by the drug that would later be marketed as Caverject.

How the name came about: Caver= Corpus Cavernosum, the tissues inside the penis that fill with blood to make an erection. Ject = well, as Upjohn told us, “the ‘ject’ part speaks for itself, doesn’t it.”

Rejected names: They wouldn’t give us any, “It’d change the way we brainstorm and affect our creativity.”

Downside: It’s injected. Though according to the New York Times, “Some men prefer local injections to pills.”

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with the Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

AN IMPORTANT UPDATE

We’re falling behind our online fundraising goals and we can’t sustain coming up short on donations month after month. Perhaps you’ve heard? It is impossibly hard in the news business right now, with layoffs intensifying and fancy new startups and funding going kaput.

The crisis facing journalism and democracy isn’t going away anytime soon. And neither is Mother Jones, our readers, or our unique way of doing in-depth reporting that exists to bring about change.

Which is exactly why, despite the challenges we face, we just took a big gulp and joined forces with the Center for Investigative Reporting, a team of ace journalists who create the amazing podcast and public radio show Reveal.

If you can part with even just a few bucks, please help us pick up the pace of donations. We simply can’t afford to keep falling behind on our fundraising targets month after month.

Editor-in-Chief Clara Jeffery said it well to our team recently, and that team 100 percent includes readers like you who make it all possible: “This is a year to prove that we can pull off this merger, grow our audiences and impact, attract more funding and keep growing. More broadly, it’s a year when the very future of both journalism and democracy is on the line. We have to go for every important story, every reader/listener/viewer, and leave it all on the field. I’m very proud of all the hard work that’s gotten us to this moment, and confident that we can meet it.”

Let’s do this. If you can right now, please support Mother Jones and investigative journalism with an urgently needed donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate